All Updates

All Updates

icon
Filter
Funding
Alumis raises USD 250 million in IPO and concurrent private placement to support Phase III clinical trials of plaque psoriasis drug candidate 'ESK-001'
Precision Medicine
Jun 28, 2024
This week:
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
Precision Medicine
Yesterday
M&A
Ipsen licenses Foreseen's antibody-drug conjugate 'FS001' for first-in-class cancer treatment development
AI Drug Discovery
Yesterday
Partnerships
Beacon Therapeutics collaborates with Abeona Therapeutics for ophthalmic gene therapy development
Cell & Gene Therapy
Yesterday
Funding
Pan Cancer T raises EUR 4.25 million in seed extension funding for preclinical studies of PCT1:CO-STIM TCR T-cell therapy
Cell & Gene Therapy
Yesterday
Partnerships
Accelerated Biosciences and Pluristyx partner to create clinical-grade induced pluripotent stem cell lines
Cell & Gene Therapy
Yesterday
M&A
SoftBank acquires UK AI chipmaker Graphcore to improve AI capabilities
Edge Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 28, 2024

Alumis raises USD 250 million in IPO and concurrent private placement to support Phase III clinical trials of plaque psoriasis drug candidate 'ESK-001'

Funding

  • Alumis has secured USD 250 million in an initial public offering (PO) and concurrent private placement. The IPO involves the sale of ~13.1 million shares priced at USD 16.00 per share. The offering is expected to close on July 1. The concurrent private placement involves the sale of ~2.5 million shares at USD 16.00 per share to existing investor AyurMaya Capital Management Fund, expected to close after the closing of the initial public offering on or before July 22, 2024.

  • The combined proceeds will be used to conduct multiple Phase III trials on Alumis's leading asset, ESK-001, to treat moderate to severe plaque psoriasis.

  • Analyst QuickTake: In June 2024 , Alumis revealed its plan to raise ~USD 300 million from the IPO by issuing 17.65 million shares at a target price between USD 16 and USD 18 per share. Downsizing the offering, the company sold 13.1 million shares at the low end of the target price range. The IPO is one of the largest of the year within the biotech sector.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.